Jove
Visualize
Contact Us

Related Experiment Videos

Interleukin-2: SILCAAT study to continue

    Project Inform Perspective
    |December 31, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Researchers successfully negotiated to continue the important SILCAAT study of interleukin-2 (IL-2, Proleukin) after Chiron Corporation

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Oncology
    • Immunotherapy
    • Clinical Trials

    Background:

    • Chiron Corporation was conducting a pivotal study on interleukin-2 (IL-2, Proleukin).
    • The company announced the discontinuation of this significant clinical trial in late 2002.
    • This decision raised concerns among researchers and patient advocates regarding the study's future.

    Discussion:

    • Researchers and activists advocated for the continuation of the SILCAAT study.
    • Negotiations between stakeholders and Chiron Corporation aimed to prevent the study's termination.

    Key Insights:

    • A successful transition of the SILCAAT study to independent researchers was achieved in February 2003.
    • This initiative preserved critical ongoing research into interleukin-2 therapy.

    Outlook:

    • The continuation of the SILCAAT study allows for further data collection and analysis.
    • Independent oversight ensures the integrity and progress of interleukin-2 research.